ReviewJournal of Parkinson's disease2016
Structural Imaging and Parkinson's Disease: Moving Toward Quantitative Markers of Disease Progression.
Review in Journal of Parkinson's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- α-Synuclein aggregation and brain atrophy in SNCA-A53T transgenic monkeys are correlated with parkinsonism.Brain : a journal of neurology · 2026Article
- Longitudinal brain morphometry in Parkinson's disease clinical subtypes: Distinct signatures forecast behavioral change within subtypes.Parkinsonism & related disorders · 2026Article
- An Explainable Approach to Parkinson's Diagnosis Using the Contrastive Explanation Method-CEM.Diagnostics (Basel, Switzerland) · 2025Article
- Multivariate Associations Between Neurophysiological Activity and Sensory Motor Cortical Morphometry in Parkinson's Disease.bioRxiv : the preprint server for biology · 2025Article
- Shared and distinct cortical morphometric alterations in five neuropsychiatric symptoms of Parkinson's disease.Translational psychiatry · 2024Article
- Clinical symptoms and neuroanatomical substrates of daytime sleepiness in Parkinson's disease.NPJ Parkinson's disease · 2024Article
- PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.American journal of nuclear medicine and molecular imaging · 2024Review
- Pinpointing the precise stimulation targets for brain rehabilitation in early-stage Parkinson's disease.BMC neuroscience · 2023Article
- Texture-based markers from structural imaging correlate with motor handicap in Parkinson's disease.Scientific reports · 2021Article
- Brain atrophy progression in Parkinson's disease is shaped by connectivity and local vulnerability.Brain communications · 2021Article
- It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimer's and Lewy Body Disease Spectra.Frontiers in systems neuroscience · 2021Review
- Six Visual Rating Scales as A Biomarker for Monitoring Atrophied Brain Volume in Parkinson's Disease.Aging and disease · 2020Article
- Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Spatial judgment in Parkinson's disease: Contributions of attentional and executive dysfunction.Behavioral neuroscience · 2019Article
- Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorder.Sleep · 2019Article
- Whole Exome Sequencing Study of Parkinson Disease and Related Endophenotypes in the Italian Population.Frontiers in neurology · 2019Article
- Brain MRI Reveals Ascending Atrophy in Parkinson's Disease Across Severity.Frontiers in neurology · 2019Article
- Regional Structural Hippocampal Differences Between Dementia with Lewy Bodies and Parkinson's Disease.Journal of Parkinson's disease · 2019Article
- Imaging of Motor Cortex Physiology in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2018Review
- Impulsivity in Parkinson's Disease Is Associated With Alterations in Affective and Sensorimotor Striatal Networks.Frontiers in neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease (PD) is a progressive age-related neurodegenerative disorder. Although the pathological hallmark of PD is dopaminergic cell death in the substantia nigra pars compacta, widespread neurodegenerative changes occur throughout the brain as disease progresses. Postmortem studies, for example, have demonstrated the presence of Lewy pathology, apoptosis, and loss of neurotransmitters and interneurons in both cortical and subcortical regions of PD patients. Many in vivo structural imaging studies have attempted to gauge PD-related pathology, particularly in gray matter, with the hope of identifying an imaging biomarker. Reports of brain atrophy in PD, however, have been inconsistent, most likely due to differences in the studied populations (i.e. different disease stages and/or clinical subtypes), experimental designs (i.e. cross-sectional vs. longitudinal), and image analysis methodologies (i.e. automatic vs. manual segmentation). This review attempts to summarize the current state of gray matter structural imaging research in PD in relationship to disease progression, reconciling some of the differences in reported results, and to identify challenges and future avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.